JPRN-jRCTs031180013
Active, not recruiting
Phase 2
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker - IMMUNITY-ONE(NEJ029B)
Kagamu Hiroshi0 sites60 target enrollmentStarted: August 7, 2018Last updated:
Overview
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Kagamu Hiroshi
- Enrollment
- 60
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •1\.Advanced non\-small\-cell lung cancer
- •2\.History of one regimen or more cytotoxic chemotherapy
- •3\.Twenty years and over
- •4\.Expect survival for more than 3 months
- •5\.ECOG PS 0\-1
- •6\.Having measurable leasions
- •7\.Main organs function is maintained
- •8\.With consent of the person or the substitute
Exclusion Criteria
- •1\.Having history of immuno\-checkpoint\-inhibitor
- •2\.Having history of autoimune disease
- •3\.Having active or symptomatic interstitial lung disease
- •4\.With infections requiring systemic treatment
- •5\.Having symptomatic brain metastasis
- •6\.Having poorly controlled diabetes
- •7\.Having active liver disease
- •8\.Having history of severe hypersensitivity
- •9\.Patient judged inappropriate by the attending physician
Investigators
Similar Trials
Completed
Not Applicable
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkernon-small-cell lung cancerJPRN-UMIN000028468orst East Japan Study Group(NEJSG)60
Completed
Phase 2
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Studypleural mesothelioma10027412NL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
Active, not recruiting
Not Applicable
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Active, not recruiting
Phase 1
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkiCTIS2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61
Recruiting
Phase 2
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61